


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for Form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 1

1

of

1

<i>Complete if Known</i>	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
RW	1	US-4,053,638	10-11-77	Litchfield et al.	
PO	2	US-4,083,974	04-11-87	Turi	
RW	3	US-4,339,440	07-13-82	Bajusz et al.	
RW	4	US-5,918,568	07-06-99	Gjerløv	
PO	5	US-6,110,908	08-29-00	Guthery	
PO	6	US-6,143,790	11/07/00	Hallinan et al.	
PO	7	US-6,448,058 B1	09-10-02	Patel et al.	
PO	8	US-6,613,879 B1	09-02-03	Firestone et al.	


FOREIGN PATENT DOCUMENTS

Examiner's Signature	<u>Alesar</u>	Date Considered	5/5/05
----------------------	---------------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

of

1

Complete if Known

Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

**Examiner's
Signature**

Roser


Date Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Institute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE et al.
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RD	1	US-6,159,706	12-12-2000	Shepard	
RD	2	US-6,245,750	06-12-2001	Shepard	
RD	3	US-6,339,151	01-15-2002	Shepard et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
RD	4	WO 99/08110	02-18-1999	NewBiotics, Inc.		
RD	5	WO 99/37753	07-29-1999	NewBiotics, Inc.		
RD	6	WO 01/07454 A1	02-01-2001	NewBiotics, Inc.		
RD	7	WO 98/13059 A	04-02-1998	Squibb Bristol Myers		

Examiner's Signature

RDesai

Date Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE, et al.
Art Unit	1623
Examiner Name	Unassigned

Attorney Docket Number

NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	1	APFEL, C. et al. "Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents" (2000) <i>J. Med. Chem.</i> 43:2324-2331	
	2	APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in <i>escherichia coli</i> cell homogenates and intact cells" (April, 2001a) <i>Anti. Agents and Chemo.</i> 45(4):1053-1057	
	3	APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Target validation and resistance development" (April, 2001b) <i>Anti. Agents and Chemo.</i> 45(4):1058-1064	
	4	BECKER, A. et al. "Iron center, substrate recognition and mechanism of peptide deformylase" (1998) <i>Nat. Struct. Biol.</i> 5(12):1053-1058	
	5	CHAN, Michael K. et al. "Crystal structure of the <i>escherichia coli</i> peptide deformylase" <i>Biochem.</i> (1997) 36:13904-13909	
	6	CHEN, D.Z. et al. "Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor" (2000) <i>Biochem.</i> 39(6):1256-1262	
	7	CLEMENTS, J.M. et al. "Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor" (February, 2001) <i>Anti. Agents and Chemo.</i> 45(2):563-570	
	8	de GROOT, F.M.H. et al. "Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin" (2000) <i>J. Med. Chem.</i> 43:3093-3102	
	9	DUBOWCHICK, G.M. et al. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin, <i>Bioorg & Medicinal Chem. Letters</i> 8(23):3341-3346.	
	10	DURAND, D.J. et al. "Peptide deformylase inhibitors of bacterial peptide deformylases" (July 15, 1999) <i>Arch. Biochem. And Biophysics.</i> 367(2): 297-302	
	11	GIGLIONE, C. et al. "Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents" (2000a) <i>Mol. Microbiol.</i> 36(6):1197-1205	
	12	GIGLIONE, C. et al. "Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms" <i>EMBO J.</i> (2000b) 19(21):5916-5929	
	13	HAO, B. et al. "Structural basis for the design of antibiotics targeting peptide deformylase" (1999) <i>Biochem.</i> 38(15):4712-4719	
	14	HU, Y.J. et al. "H-phosphonate derivatives as novel peptide deformylase inhibitors" (1998) <i>Bioorg Med Chem Letts.</i> 8(18):2479-2482	
	15	HUNTINGTON, K.M. et al. "Synthesis and antibacterial activity of peptide deformylase inhibitors" (2000) <i>Biochem.</i> 39(15):4543-4551	
	16	JAYASEKERA, M.M.K. et al. "Novel nonpeptidic inhibitors of peptide deformylase" (Sept. 15, 2000) <i>Arch. Biochem. & Biophys.</i> 381(2):313-316	
	17	LACKEY, D.B. et al. (2001) Enzyme - catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB 1011 by thymidylate synthase, <i>Biochem. Pharmacology</i> 61:179-189	
	18	MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" (1999) <i>Pathol. Biol.</i> 47(8):780-783	

Examiner's Signature

Rosario

Date Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known	
				Application Number	10/714,255
				Filing Date	November 14, 2003
				First Named Inventor	Carlo BALLATORE, et al.
				Art Unit	1623
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	NB 2020.01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					

NON PATENT LITERATURE DOCUMENTS

Examiner's Signature	<u>Raezer</u>	Date Considered	5/5/05
-------------------------	---------------	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.